aflibercept + S-1

Aflibercept + S-1 is an investigational **combination regimen** evaluated in clinical trials for the treatment of advanced solid tumors. **Aflibercept** is a recombinant fusion protein that binds to and inhibits vascular endothelial growth factors (VEGF-A, VEGF-B) and placental growth factor, thereby blocking angiogenesis and tumor progression. **S-1** is an oral fluoropyrimidine formulation containing tegafur (a prodrug of 5-fluorouracil), gimeracil (an inhibitor of 5-FU catabolism), and oteracil (which reduces gastrointestinal toxicity by decreasing 5-FU activation in the gut). The combination aims to provide additive or synergistic anti-cancer effects by combining anti-angiogenic therapy with cytotoxic chemotherapy. It has been studied in Japanese patients with metastatic or unresectable solid malignancies, primarily in phase I trials to assess safety, tolerability, and recommended dosing. The combination is administered as intravenous aflibercept every two weeks plus oral S-1 in cycles[1].

Brand names

aflibercept + S-1

Other names

aflibercept + S-1